scholarly journals Association of molecular biomarkers heterogeneity and treatment pattern, disease outcomes in multifocal or multicentric breast cancer patients

2021 ◽  
Author(s):  
Shuai Li ◽  
Jiayi Wu ◽  
Ou Huang ◽  
Jianrong He ◽  
Li Zhu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Endocrine Therapy ◽  
Disease Free Survival ◽  
Treatment Pattern ◽  
Adjuvant Endocrine Therapy ◽  
Breast Cancer Patients ◽  
Ki 67 ◽  
Disease Outcomes ◽  
Tumor Focus ◽  
Multicentric Breast Cancer

Abstract Purpose To evaluate the rates of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67 heterogeneity in multifocal or multicentric breast cancer (MMBC) and its association with treatment pattern and disease outcomes. Methods MMBC patients with ER, PR, HER2, and Ki67 results for each tumor focus were retrospectively analyzed and categorized into the Homo group and the Hetero group. Chi-square test were performed to compare the treatment options between the groups. Disease-free survival (DFS) and overall survival (OS) rates were estimated from Kaplan-Meier curves and compared between two groups. Results A total of 330 patients were included and 53 (16.1%) were classified into the Hetero group. Adjuvant endocrine therapy was more frequently assigned for patients in the Hetero group than in the Homo group (84.9% vs. 71.7%, P = 0.046). There was no difference in terms of adjuvant anti-HER2 therapy (28.3% vs. 19.6%, P = 0.196) and chemotherapy (69.9% vs. 69.8%, P = 0.987) usage between two groups. At a median follow-up of 36 months, DFS rates were 81.2% for the Hetero group and 96.5% for the Homo group (HR = 2.81, 95% CI: 1.00-7.88, P = 0.041). The estimated 3-year OS rates for the groups were 95.8% and 99.5%, respectively (HR = 4.31, 95% CI: 0.83–22.46, P = 0.059). Conclusion Heterogeneity of ER, PR, HER2, or Ki67 was present in 16.1% patients with MMBC. Biomarkers heterogeneity influenced adjuvant endocrine therapy usage and was associated with worse disease outcomes, indicating further clinical evaluation.

Opioid use among female breast cancer patients using different adjuvant endocrine therapy regimens

2017 ◽  
Vol 165 (2) ◽  
pp. 455-465 ◽  
Author(s):  
Xi Tan ◽  
Tareq Fabian Camacho ◽  
Virginia T. LeBaron ◽  
Leslie J. Blackhall ◽  
Rajesh Balkrishnan
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Female Breast Cancer ◽  
Adjuvant Endocrine Therapy ◽  
Breast Cancer Patients ◽  
Opioid Use ◽  
Female Breast

scholarly journals Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy

The Breast ◽  
2012 ◽  
Vol 21 (5) ◽  
pp. 662-668 ◽  
Author(s):  
Mathilde S. Larsen ◽  
Karsten Bjerre ◽  
Anne E. Lykkesfeldt ◽  
Anita Giobbie-Hurder ◽  
Anne-Vibeke Lænkholm ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Adjuvant Endocrine Therapy ◽  
Breast Cancer Patients ◽  
Er Positive ◽  
Predicting Outcome ◽  
Positive Breast Cancer

BIG 1–98: A randomized double-blind phase III study comparing letrozole and tamoxifen given in sequence vs. alone as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. LBA528-LBA528
Author(s):  
H. T. Mouridsen ◽  
A. Keshaviah ◽  
L. Mauriac ◽  
J. Forbes ◽  
R. Paridaens ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Postmenopausal Women ◽  
Endocrine Therapy ◽  
Disease Free Survival ◽  
Adjuvant Endocrine Therapy ◽  
Phase Iii ◽  
Study Entry ◽  
Second Primary ◽  
Efficacy Analysis ◽  
Disease Free

LBA528 Background: The Primary Core Analysis (PCA) of BIG 1–98 comparing letrozole (L) to tamoxifen (T) as initial adjuvant endocrine therapy showed that L significantly prolonged disease-free survival (DFS), particularly reducing the risk of relapse in distant sites, compared with T for postmenopausal women with endocrine-responsive breast cancer (BC). The aim of the Second Primary Analysis (SPA) is to compare L and T given in sequence vs. alone. On Mar 15, ‘06, the Data Safety Monitoring Committee (DSMC) will review the results of the 2nd interim analysis of the SPA. We will present safety and efficacy data from this analysis if the DSMC recommends release of the results. Methods: 8028 women were randomized upfront to Tx5 years (yrs) (A), Lx5 (B), Tx2→Lx3 (C), or Lx2→Tx3 (D); 1835 to the 2-arm option of the study (arm A vs. B; Mar ’98 - Mar ‘00) and 6193 to the 4-arm option (arm A vs. B vs. C vs. D; Apr ’99 - May ‘03). The primary endpoint was DFS (time from randomization to first occurrence of invasive BC recurrence, invasive contralateral BC, second non-breast malignancy, or death from any cause). The SPA is comprised of two pair-wise comparisons: arm A vs. C and B vs. D. Only 4-arm patients (pts) alive and disease-free at 2 yrs after study entry (corresponding to the treatment switch for arms C and D) are included. These analyses will determine if the risk of an event beyond 2 yrs is reduced by switching agents. Additional exploratory analyses based on all events and follow-up (FU) for 4-arm pts will be conducted, including the comparison of arm B vs. C. The final SPA is planned for Feb ‘08, after 662 events. In Jan ‘05, the 1st interim efficacy analysis was presented to the DSMC, after 162 events among 3641 pts (excluding those who had an event within 2 yrs or did not yet have at least 2 yrs of FU). The median SPA FU (from 2 yrs after study entry) was 11.1 months. The 2nd interim efficacy analysis will be presented to the DSMC on Mar 15, ‘06 based on data received as of a Dec 21, ‘05. Results: Conclusions: No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document